Geir Åge Løset

Zelluna Immunotherapy AS engages in research and development on biotechnology. The company is headquartered in Oslo, Norway.

Radiumhospitalets Forskningsstiftelse invests in companies from Nordic research institutions. It is a pre-seed investor and project developer focused on cancer. It strengthens cancer research at Rikshospitalet University Hospital, including The Norwegian Radium Hospital. It provides Oslo Cancer Cluster with the necessary infrastructure and management team, as well. The company was founded in 1986 and is headquartered in Lysaker, Norway.

Pfizer AS operates as biopharmaceutical company, which engages in the development and manufacture of pharmaceutical products. It develops and produces medicines such as penicillin; vaccines; and medicines for the treatment of cancer, pain, cardiovascular disease, diabetes, mental illness, and rheumatism. The firm also offers drugs against parasites. The company was founded on November 25, 1959 and is headquartered in Oslo, Norway.

APIM Therapeutics AS develops and commercializes novel anti-cancer therapies. It offers a physiological intervention point allowing the potentiation of the action of clinical drugs across multiple cancer indications. The company focuses on the development and commercialization of novel anti-cancer therapies potentiating chemo-therapy induced responses in cancer cells. The company was founded by Marit Otterlei in 2009 and is headquartered in Trondheim, Norway.

Birk Venture AS (Birk Venture) is an independent Scandinavian venture capital firm which was founded in 2010 by Hans Ivar Robinson. Based in Oslo, Norway, the firm focuses exclusively on the life science industry, utilizing their industry experience and international network to partner with young companies with significant growth prospects.

Oslo Cancer Cluster NCE is an oncology research firm that specializes in developing cancer diagnostics and medicines. The private company is based in Oslo, Norway.

AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden.

Part of Ernst & Young Global Ltd., Ernst & Young AS is a Norwegian company that provides accounting services. The company is based in Oslo, Norway. The CEO of the company is Christin Erichsen Bøsterud.

Rikshospitalet HF operates hospitals and healthcare centers. The private company is based in Oslo, Norway.

Accession Therapeutics Limited is a British biotech company that is developing novel immuno-oncology therapeutics to eradicate cancers by harnessing the immune system more powerfully than ever before. The company is based in Oxford, UK and was founded in 2020 by Bent K. Jakobsen, who has been the CEO since then. The company's product, Trocept, is the first approach that meets the three requirements of being highly specific, broad in action to kill all cancer cell variants present, and potent in activating the full immune system arsenal local to the tumour. The team is built around successful biotech entrepreneurs experienced in taking projects through to the clinic and is supported by a Board comprising experienced international healthcare investors.

Uni Targeting Research AS is a holding company that provides the biopharmaceutical industry with tools and services for mammalian cell-line based development procedures and production processes. It offers upstream solutions to reduce complementary deoxyribonucleic acid and mammalian cell-line based timelines and increase protein production yields. Its technology enables both enhanced synthesis/secretion of naturally secreted proteins, and secretion of intracellular proteins. Its services include vector improvement, tailor-made vectors, and tool proteins. The company was founded by Ian Fraser Pryme, John E. Hesketh, Albert Tauler, and Beate Stern in 2001 and is headquartered in Bergen, Norway.

Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland.

ExpreS2ion Biotechnologies ApS operates as a biotechnology company which engages in the field of protein production in Drosophila Schneider-2 cells. Its services include custom proteins and research & development reagents, process development, and feasibility studies. The company was founded by Charlotte Dyring, Martin Roland Jensen, and Willem Adriaan de Jongh in 2009 and is headquartered in Horsholm, Denmark.

Part of Artbio, Inc., Artbio AS is a clinical-stage radiopharmaceutical biotechnology business that works to create a new class of alpha radio ligand medicines. The company is based in Oslo, Norway. The Norwegian company was founded in 2018. The CEO is Emanuele Ostuni.